THE CLINICAL TRIAL
Macrophage Activation Syndrome (MAS) is due to an overactive immune system and sometimes described as an entire body inflammatory response. It can cause fever, low blood cell counts, clotting problems, enlargement of the liver and spleen, very high triglyceride levels, and abnormal liver function. The purpose of the Emerald Studies was to see if the investigational drug efficiently reduced the inflammation observed in MAS patients.
THE PROJECT
The Sponsor’s goal was to accelerate patient recruitment for this clinical study using a suite of patient recruitment materials developed by the Stark / Raving Health team. The program oversaw a global clinical study with highly specific recruitment criteria. Our approach focused on establishing a unique study brand identity combined with recruitment and educational materials that engaged and empowered patients to consider participation.